drugset / Trial / NCT04716946
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
Phase 2
Active not recruiting
13 enrolled
Memorial Sloan Kettering Cancer Center
AstraZeneca · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether treatment with the study drug durvalumab combined with a type of radiation therapy called stereotactic body radiation (SBRT) is a more effective treatment for early-stage non-small cell lung cancer (NSCLC) than SBRT alone.
Timeline
- Start
- 2021-01-27
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |